| Assessment Status | Rapid Review Complete |
| HTA ID | 25006 |
| Drug | Amivantamabin in combination with lazertinib |
| Brand | Rybrevant®) in combination with Lazcluze® |
| Indication | Amivantamab in combination with lazertinib is indicated for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations. |
| Assessment Process | |
| Rapid review commissioned | 28/01/2025 |
| Rapid review completed | 05/03/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of amivantamab in combination with lazertinib compared with the current standard of care. |
